Your Article Summary
Phase I Testing to Commence on Second Compound Developed from AMRI, Bristol-Myers Squibb Collaboration
Bristol Myers-Squibb Company, 05/27/09
AMRI announced that Bristol-Myers Squibb Company has submitted a Clinical Trial Application to the Medical Products Agency in Sweden for approval to initiate Phase I studies on an AMRI compound exclusively licensed to Bristol-Myers Squibb. Upon approval of the CTA by the MPA, Bristol-Myers Squibb may begin Phase I testing in Sweden.
Today in M&A/Partnerships...keeping you current
Receive free subspecialty "5-minute updates" via email
Array BioPharma and Amgen Partner in Type 2 Diabetes
Amgen, 12/15/09
Inno Biologics and CEVEC Sign License Agreement for Human CAP Technology
b3c newswire, 12/09/09
Federal Advisory Committees to Meet
HealthDataManagement, 12/09/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
GSK study showed targeted therapy combination achieved 14 month overall survival in patients with advanced breast cancer
GlaxoSmithKline, 12/15/09
New Phase II Study Showed Trastuzumab-DM1 Shrank Tumors in Women With Highly Advanced HER2-positive Breast Cancer
Genentech, 12/15/09
GSK and Intercell form strategic alliance to develop and commercialise innovative needle-free patch-based vaccines
GlaxoSmithKline, 12/15/09
Article Search
Sponsor


See Latest Articles


